Getty Images
Posted: 06/21/2010
WASHINGTON - Federal health experts meet this week to review the first pill designed to boost the female sex drive, more than a decade after Pfizer's drug Viagra sparked the search for a female counterpart.
But even if the drug from Boehringer Ingelheim wins approval, experts say it will probably fall short of blockbuster sales due to limited effectiveness and skepticism about the usefulness of pharmaceuticals for boosting female libido.
In its review posted online, the Food and Drug Administration says two Boehringer studies failed to show a significant increase in sexual desire, though women did report more sexually satisfying experiences.
FDA regulators also noted side effects like depression, fainting and dizziness among women taking the pill.
Copyright AP Modified, Copyright 2010 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
Health
A new study led by an associate professor of family studies at the University of New Hampshire found bullying by siblings can cause just as much damage as bullying by peers.
Expectant mothers who are overweight may be jeopardizing their baby's health.
There’s a new danger for people suffering from sleep apnea.
Trending Now
Last week we told you about dozens to layoffs to teachers in Harford County.
Now we can tell you the teachers that remain, will face new challenges once classes start up again in the Fall.
Parents can now watch their young teen drivers without getting into the car.
The Anne Arundel County Health Department is warning residents not to swim at three county beaches.
After being beaten at Camden Yards last month, Matthew Fortese is finally out of Shock Trauma and beginning rehab but his family is still looking for answers.